Placement pour lever 4.2 millions de dollars américains
29 Février 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
DES SONDAGES DE MARCHÉ ONT ÉTÉ RÉALISÉS CONCERNANT LES QUESTIONS CONTENUES DANS CETTE ANNONCE, AVEC POUR RÉSULTAT QUE CERTAINES PERSONNES ONT PRIS CONNAISSANCE DE TELLES INFORMATIONS PRINCIPALES. Dès la publication de cette annonce, ces informations privilégiées sont désormais considérées comme appartenant au domaine public et ces personnes cesseront donc d'être en possession d'informations privilégiées.
Hemogenyx Pharmaceuticals plc
(« Hemogenyx Pharmaceuticals » ou la « Société »)
Placing to Raise US 4.2 millions de dollars
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully raised US$4.2 million (£3.325 million) before expenses through the allotment and issue of 166,250,000 new ordinary shares at 2 pence per share (the "Placing", "Placing Shares").
The net proceeds from the Placing will be used to facilitate the development of the Company's Chimeric Antigen Receptor T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia ("AML"). As announced on 9 February 2024, the Company was informed by the U.S. Federal Food and Drug Administration ("FDA") that it had lifted the clinical hold on the Investigational New Drug ("IND") application for HEMO-CAR-T for the treatment of AML. The funds have been raised to allow the Company to progress HEMO-CAR-T to phase 1 clinical trials.
An application is being made to the London Stock Exchange Main Market and admission of the Placing Shares to trading is expected on or around 6 March 2024 ("Admission"). The Placing Shares will rank pari passu avec les actions ordinaires existantes de la Société.
Le Dr Vladislav Sandler, PDG et co-fondateur de Hemogenyx Pharmaceuticals, a déclaré :
"We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T. I would like to thank new and existing shareholders for their support and for contributing to this sizeable fundraise in difficult market conditions. The recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I am very grateful."
Droits de vote totaux
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 1,341,815,988 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
For the purposes of UK MAR, the person responsible for arranging for the release of this Announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquêtes
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, PDG et co-fondateur | |
Peter Redmond, directeur | |
SP Angel Corporate Finance LLP | Téléphone : +44 (0) 20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limitée | Téléphone : +44 (0) 20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
À propos de Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
La Société est un groupe biopharmaceutique au stade préclinique qui développe de nouveaux médicaments et traitements pour traiter les maladies sanguines et auto-immunes et pour apporter le pouvoir curatif de la greffe de moelle osseuse à un plus grand nombre de patients souffrant de maladies potentiellement mortelles incurables. Hemogenyx Pharmaceuticals développe plusieurs produits candidats distincts et complémentaires, ainsi que des plateformes technologiques qu'elle utilise comme moteurs pour le développement de nouveaux produits.
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.